Obermatt

Turn Therapeutics

NMQ:TTRX · US90021W1053
PharmaceuticalsX-Small

360° View

65
Price/Sales93
Price/Earnings95
Price/Book6
Dividend Yield1
Revenue Growth
Profit Growth58
Capital Growth6
TSR 52w18
Leverage23
Liquidity83
Refinancing28
Combined65
Analyst Opinions100
Pro Holdings5
Opinion Changes50
Market Pulse9

Profile

CountryUSA
IndustryPharmaceuticals
SizeX-Small
TypePublic Company
ExchangeNASDAQGM
Founded2015
Employees10
ISINUS90021W1053
Last UpdateApr 2, 2026
Index & Theme
Chronic DiseasesDermatologyOphthalmologyPain ManagementMedicalMedical DevicePharmaceutical

Description

Turn Therapeutics Inc. operates as a pharmaceutical and medical device development company built around a proprietary platform technology designed to enhance drug performance. The company's patented mixing process, commercially referred to as PermaF…

Analysis

Turn Therapeutics's 360° View rank of 65 places it above its peer average — better than 65% of its true peers.

It's lagging on growth (22) and looks cheap versus peers (100). On safety it is carrying more balance-sheet risk (37), and the market shows skeptical sentiment (11). Taken together, its Combined rank of 65 reads as above its peer average.

Detailed & Historical Ranks

Deep dive into 15 detailed ranks and 3 years of history.

Current202520242023
Price/Sales
93
Price/Earnings
95
Price/Book
6
Dividend Yield
1
Value (overall)
100

Cells are coloured by rank band (red weak → green strong). Sentiment & 360° history begins 2023.

Similar Stocks

The companies this stock is ranked against.

Compare Turn Therapeutics with its peers
Fulcrum Therapeutics
NMQ:FULC
24
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Journey Medical Corporation
NAQ:DERM
73
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →
Insmed
NSQ:INSM
51
CountryUSA
IndustryBiotechnology
SizeMedium
Full Stock Analysis →
Ligand Pharmaceuticals
NMQ:LGND
64
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Amphastar Pharmaceuticals
NSQ:AMPH
63
CountryUSA
IndustryPharmaceuticals
SizeMedium
Full Stock Analysis →
Assertio Therapeutics
NAQ:ASRT
34
CountryUSA
IndustryPharmaceuticals
SizeSmall
Full Stock Analysis →

Make Sense of the Ranks

Every rank runs 1–100 against true peers. Higher is always better.

360° View
1 · Watch OutGood· 100
Value
1 · ExpensiveGood Value· 100
Quality
1 · Weak FundamentalsHigh Quality· 100
Growth
1 · Tough TimesHigh Growth· 100
Safety
1 · High LeverageWell-Financed· 100
Sentiment
1 · SkepticismPositive· 100
Learn More →